Ixomida
Hormonal antineoplastic agent Antiandrogen indicated for the treatment of patients with metastatic castration-sensitive prostate cancer or with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of progression.
Therapeutic Area
Oncology + Uro-Oncology
Active Ingredient
Apalutamide
Line
Oncology + Uro-Oncology
Dosage forms
60Mg coated tablets x 120 tablets
